53 reports of this reaction
2.2% of all CEFPROZIL reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for CEFPROZIL, manufactured by Ascend Laboratories, LLC. There are 53 FDA adverse event reports linking CEFPROZIL to DYSPNOEA. This represents approximately 2.2% of all 2,368 adverse event reports for this drug.
Patients taking CEFPROZIL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CEFPROZIL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CEFPROZIL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 53 FDA reports for CEFPROZIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for CEFPROZIL, making it a notable side effect.
If you experience dyspnoea while taking CEFPROZIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.